DRG Market Assessment reports

The chronic myeloid leukemia (CML) drug-treatment market is dominated by BCR-ABL tyrosine kinase inhibitors, notably imatinib (Novartis’s Gleevec; generics); these agents enable many CML patients…

The prevalence of HBV is a major public health concern in China. Patients chronically infected with HBV are at high risk of developing hepatic cirrhosis and hepatocellular carcinoma. The majority…

Multiple sclerosis (MS), a chronic immune-mediated disease of the nervous system, is classified as a rare disease in China because of its low prevalence in that country. Traditionally, MS patients…

Cystic fibrosis (CF) is a genetic disease caused by any one of the more than 2,000 mutations identified in the cystic fibrosis transmembrane conductance regulator (CFTR) gene; such mutations lead…

Hyperkalemia is a potentially life-threatening condition in which serum potassium concentration exceeds 5.5 mEq/L. Despite various guidelines, no accepted consensus exists for the management of…

Key benefits and uses Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting Drill down into physicians’ treatment sequences and understand whom to…

Ulcerative colitis (UC) is a chronic intermittent relapsing disorder of the large intestine and rectum. Treatment typically begins with conventional agents (e.g., 5-aminosalicylic acids [5-ASAs])…

China has the highest incidence of gastroesophageal cancer in the world. Chemotherapy is the main treatment, although targeted therapies such as trastuzumab (an anti-HER2 MAb for HER2-positive…

Two types of pharmacotherapy are used to treat adult asthma: rescue drugs and maintenance therapies. Rescue drugs are inhaled therapies (e.g., a SABA such as Teva’s ProAir HFA) that treat the…

Breast cancer is the most prevalent malignancy in women in China. Chemotherapy was the mainstay of treatment, but China now has access to several cutting-edge premium-priced targeted therapies (e.g…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key MN patient populations, covering 171 countries and more than 99% of…

Hormone receptor (HR)-positive / HER2-negative breast cancer is the most prevalent breast cancer subtype. Targeted therapies aimed at CDK4/6 inhibition (Pfizer’s Ibrance, Novartis’s Kisqali,…